PBT2 Takes a Dive in Phase 2 Alzheimer’s Trial
IMAGINE that: Amyloid deposition shrinks in both treatment and placebo groups, dealing a blow to the anti-aggregation drug PBT2.
22 RESULTS
Sort By:
Go to another page:
IMAGINE that: Amyloid deposition shrinks in both treatment and placebo groups, dealing a blow to the anti-aggregation drug PBT2.
Researchers identify a transcription factor that protects neurons during normal aging but goes AWOL in Alzheimer’s brains.
Hardening of the arteries correlated with greater amyloid deposition in a longitudinal study, strengthening ties between cardiovascular disease and Alzheimer’s.
Low levels of 10 phospholipids in blood plasma correlated with future cognitive decline in older adults, hinting at diagnostic potential.
The amyloid imaging agent florbetapir predicts cognitive decline much like its forerunner, PiB.
Research suggests that the kinase Cdk5 limits formation of new memories by keeping a key synaptic receptor away from the cell surface.
Much like people with Alzheimer's, mice modelling the disease experience seizures. New research suggests that APP, and not Aβ, makes their neurons hyperexcitable.
Researchers have found protein traces of brain damage in the blood of hockey players who sustained a concussion. Could biomarkers help decide when athletes return to their sport?
A new test claims to detect Aβ oligomers in cerebrospinal fluid by exploiting their tendency to seed aggregation.
Network analysis may explain why people with semantic dementia keep making memories even as their hippocampi degenerate.
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.
The 2014 Alzheimer’s Association report finds that women bear the brunt of AD, being more likely to develop the disease or care for someone with AD full time.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
Combination Trial Debate Energizes Keystone Symposium Protecting Neurons by Ramping Up Waste Disposal? Prodromal Initiative to Identify Biomarkers for Parkinson’s Researchers Build on GWAS to Parse Genetic Players in AD and PD More than 200 researchers br
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Go to another page: